Terminally-branched polymeric linkers and polymeric conjugates containing the same
First Claim
1. A compound comprising the formula:
-
E4 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituwd cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
E1-3 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls. C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls. C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy, and at least one of E1-3 is wherein B is a (caving group, OH. a residue of a hydroxyl-containing moiety, a residue of an amine-containing moiety or wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4;
Y1-2 are independently O, S or NR9;
M is a heteroatom selected from either X or Q;
wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═
Y2);
R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy, (m1) and (m2) are independently zero or one;
(n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer;
Z is an electron withdrawing group; and
R1 is a polymeric residue of a substantially ron-antigenic polymer having a molecular weight of at least about 20,000 Daltons.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to polymeric-prodrug transport forms of the formula:
wherein:
E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy,
and at least one of E1-4 includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl-or amino-containing moiety or
wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4,
Y1-2 are independently O, S or NR9;
M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2);
R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroakoxy;
(m1) and (m2) are independently zero or one;
(n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer,
Z is an electron withdrawing group; and
R1 is a polymeric residue.
which is optionally capped with a moiety of the formula:
56 Citations
14 Claims
-
1. A compound comprising the formula:
-
E4 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituwd cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
E1-3 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls. C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls. C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy, and at least one of E1-3 is wherein B is a (caving group, OH. a residue of a hydroxyl-containing moiety, a residue of an amine-containing moiety or wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4;
Y1-2 are independently O, S or NR9;
M is a heteroatom selected from either X or Q;
wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═
Y2);
R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy, (m1) and (m2) are independently zero or one;
(n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer;
Z is an electron withdrawing group; and
R1 is a polymeric residue of a substantially ron-antigenic polymer having a molecular weight of at least about 20,000 Daltons. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
wherein (x) represents the degree of polymerization and “
Drug”
represents a residue of a hydroxyl- or amine-containing biologically active compound which has undergone a substitution reaction which results in the attachment of the biologically active moiety to the branched polymer.
-
-
3. The compound of claim 1, wherein Y1 and Y2 are oxygen.
-
4. The compound of claim 1, wherein R2-5, R7 and R8 are hydrogen.
-
5. The compound of claim 1, wherein X is selected from the group consisting of O, S, SO, SO2, C(Y3) and NR6, wherein Y3 is selected from the group consisting of O, S and R9, and R6 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls and substituted C1-6 heteroalkyls.
-
6. The compound of claim 1, wherein Q is selected from the group consisting of C2-4 alkyls, cycloalkyls, aryls, aralkyl groups substituted with a member of the group consisting of NH, O, S, —
- CH2—
C(O)—
NH—
, and ortho-substituted phenyls.
- CH2—
-
7. The compound of claim 1, wherein (p1) and (p2) are 1.
-
8. The compound of claim 1, wherein (n1) and (n2) are individually 1 or 2.
-
9. The compound of claim 1, wherein (q) is 1.
-
10. The compound of claim 1, wherein R1 comprises a polyalkylene oxide residue.
-
11. The compound of claim 10, wherein said polyalkylene oxide residue comprises polyethylene glycol.
-
12. The compound of claim 1, wherein said polymeric residue has a molecular weight of from about 20,000 to about 40,000.
-
13. The compound of claim 1, wherein B is a residue of a member of the group consisting of Ara-C, camptothecin, camptothecin analogs, paclitaxel, taxoteres, gemcitabine, podophyllotoxin, fluconazole, ciclopirox, amphoteracin B, nystatin, doxorubicin, daunorubicin, maytansine, vancomycin and erythromycin.
-
14. A method of treating a mammal with prodrugs, comprising:
administering to a mammal in need of such treatment an effective amount of a composition of claim 2.
Specification